BOSTON, Oct. 14, 2020 /PRNewswire/ — Orbita, the leading provider of HIPAA-compliant conversational voice and chat solutions for healthcare and life science organizations, today launched a new module designed to help pharmaceutical companies better detect and report adverse events. The new platform-agnostic Adverse Event module, built on the latest technology in machine learning and natural language processing, integrates into existing chat services to accurately detect and seamlessly assist users in reporting adverse reactions to medications, ultimately improving the efficiency and timeliness of adverse event reporting.
Machine learning fuels seamless and accurate reporting
Chatbots are an increasingly popular tool for patient support programs, but few are equipped to accurately flag if a patient is having a medication-induced side effect, which can hinder pharmacovigilance processes and success. Orbita’s new Adverse Event module draws from a robust corpus of medical and conversational data, while machine learning continually improves the module to increase
OptimizeRx (OPRX) is a stock that many stripes of investors could love. They appear to be a small cap company in a solid uptrend with a history of double digit revenue growth.
And the most exciting part is that they look to be an up and coming telehealth name akin to Teladoc (TDOC) but with the caveat that they have largely flown under the radar of big institutional investors.
Things are unfortunately a bit more complicated at OptimizeRx, with the largest issue being that we have very real reasons to be concerned with the accuracy of OPRX’s financial statements. But first I will parse OPRX’s flowery description of their business and demonstrate that they are largely a simple advertising company that provides digital coupons.
Clipping coupons does not = the next Teladoc
Below is language from OPRX’s latest 10-k describing their business: